Latest & greatest articles for asthma

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on asthma or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on asthma and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for asthma

101. Teaching through telemedicine: A systematic review of education-focused asthma interventions (Preprint) Full Text available with Trip Pro

Teaching through telemedicine: A systematic review of education-focused asthma interventions (Preprint) JMIR Preprints #15050: Teaching through telemedicine: A systematic review of education-focused asthma interventions Sorry, you need to enable javascript for this page to function properly. Menu Search User Sign Up Follow Us on Twitter Browse Journal Browse By Year Browse by Year: Submit Other Journals  Explore our sister journals here. Browse by Year: Browse: Maintenance Notice Due

2019 JMIR pediatrics and parenting

102. Fluticasone/formoterol (Flutiform) - the regular treatment of asthma in children aged 5 to 12 years

Fluticasone/formoterol (Flutiform) - the regular treatment of asthma in children aged 5 to 12 years 1 Published 10 June 2019 1 Product update SMC2178 fluticasone propionate/formoterol fumarate metered dose inhaler 50 microgram/5 microgram (flutiform®) Napp Pharmaceuticals Ltd 10 May 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice (...) is summarised as follows: ADVICE: following an abbreviated submission fluticasone propionate/formoterol fumarate (flutiform®) is accepted for use within NHSScotland. Indication under review: the regular treatment of asthma in children aged 5 to 12 years where the use of a combination product (an inhaled corticosteroid and a long-acting ß 2 agonist) is appropriate: • For patients not adequately controlled with inhaled corticosteroids and 'as required' inhaled short-acting ß 2 agonist. Or • For patients

2019 Scottish Medicines Consortium

103. Benralizumab (Fasenra) - treatment in adult patients with severe eosinophilic asthma

Benralizumab (Fasenra) - treatment in adult patients with severe eosinophilic asthma 1 Published 10 June 2019 1 SMC2155 benralizumab 30mg solution for injection in pre filled syringe (Fasenra®) AstraZeneca UK Limited 10 May 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE: following a full submission (...) benralizumab (Fasenra ® ) is accepted for restricted use within NHSScotland. Indication under review: As an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting ß-agonists. SMC restriction: patients with blood eosinophils =150 cells/microlitre, and either =4 prior asthma exacerbations needing systemic corticosteroids in the previous 12 months or treatment with continuous oral corticosteroids over

2019 Scottish Medicines Consortium

104. Mometasone or Tiotropium in Mild Asthma with a Low Sputum Eosinophil Level. Full Text available with Trip Pro

Mometasone or Tiotropium in Mild Asthma with a Low Sputum Eosinophil Level. In many patients with mild, persistent asthma, the percentage of eosinophils in sputum is less than 2% (low eosinophil level). The appropriate treatment for these patients is unknown.In this 42-week, double-blind, crossover trial, we assigned 295 patients who were at least 12 years of age and who had mild, persistent asthma to receive mometasone (an inhaled glucocorticoid), tiotropium (a long-acting muscarinic (...) antagonist), or placebo. The patients were categorized according to the sputum eosinophil level (<2% or ≥2%). The primary outcome was the response to mometasone as compared with placebo and to tiotropium as compared with placebo among patients with a low sputum eosinophil level who had a prespecified differential response to one of the trial agents. The response was determined according to a hierarchical composite outcome that incorporated treatment failure, asthma control days, and the forced expiratory

2019 NEJM Controlled trial quality: predicted high

105. Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma. Full Text available with Trip Pro

Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma. In double-blind, placebo-controlled trials, budesonide-formoterol used on an as-needed basis resulted in a lower risk of severe exacerbation of asthma than as-needed use of a short-acting β2-agonist (SABA); the risk was similar to that of budesonide maintenance therapy plus as-needed SABA. The availability of data from clinical trials designed to better reflect clinical practice would be beneficial.We conducted a 52-week (...) , randomized, open-label, parallel-group, controlled trial involving adults with mild asthma. Patients were randomly assigned to one of three treatment groups: albuterol (100 μg, two inhalations from a pressurized metered-dose inhaler as needed for asthma symptoms) (albuterol group); budesonide (200 μg, one inhalation through a Turbuhaler twice daily) plus as-needed albuterol (budesonide maintenance group); or budesonide-formoterol (200 μg of budesonide and 6 μg of formoterol, one inhalation through

2019 NEJM Controlled trial quality: predicted high

106. Association of Changes in Air Quality With Incident Asthma in Children in California, 1993-2014. Full Text available with Trip Pro

Association of Changes in Air Quality With Incident Asthma in Children in California, 1993-2014. Exposure to air pollutants is a well-established cause of asthma exacerbation in children; whether air pollutants play a role in the development of childhood asthma, however, remains uncertain.To examine whether decreasing regional air pollutants were associated with reduced incidence of childhood asthma.A multilevel longitudinal cohort drawn from 3 waves of the Southern California Children's Health (...) Study over a period of air pollution decline. Each cohort was followed up from 4th to 12th grade (8 years): 1993-2001, 1996-2004, and 2006-2014. Final follow-up for these data was June 2014. Population-based recruitment was from public elementary schools. A total of 4140 children with no history of asthma and residing in 1 of 9 Children's Health Study communities at baseline were included.Annual mean community-level ozone, nitrogen dioxide, and particulate matter less than 10 μm (PM10) and less than

2019 JAMA

107. Standardized Library of Asthma Outcome Measures

Standardized Library of Asthma Outcome Measures Research White Paper Standardized Library of Asthma Outcome MeasuresResearch White Paper Standardized Library of Asthma Outcome Measures Prepared for: Agency for Healthcare Research and Quality Center for Outcomes and Evidence 5600 Fishers Lane Rockville, MD 20857 www.ahrq.gov Contract No. 290-2014-00004-C Prepared by: L&M Policy Research, LLC Washington, DC 20009 With partners: OM1, AcademyHealth Investigators: Richard E. Gliklich, MD 1 Michelle (...) . For assistance contact epc@ahrq.hhs.gov. Suggested citation: Gliklich RE, Leavy MB, Li F. Standardized Library of Asthma Outcome Measures. Research White Paper. (Prepared by L&M Policy Research, LLC under Contract No. 290-2014-00004-C.) AHRQ Publication No. 19-EHC004-EF. Rockville, MD: Agency for Healthcare Research and Quality; April 2019. Posted final reports are located on the Effective Health Care Program search page. DOI: https://doi.org/10.23970/AHRQEPCLIBRARYASTHMA. iii Preface The Agency

2019 Effective Health Care Program (AHRQ)

108. Benralizumab (asthma) - Benefit assessment according to §35a Social Code Book V

Benralizumab (asthma) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Benralizumab (Asthma) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 9 May 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A18-11 Benralizumab (asthma) – Benefit (...) assessment according to §35a Social Code Book V 1 Extract of dossier assessment A18-11 Version1.0 Benralizumab (asthma) 9 May 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Benralizumab (asthma) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 15 February 2018 Internal Commission No.: A18-11 Address of publisher

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

109. Mepolizumab (Nucala) - as an add-on treatment for severe refractory eosinophilic asthma in adolescents and children aged 6 years and older

Mepolizumab (Nucala) - as an add-on treatment for severe refractory eosinophilic asthma in adolescents and children aged 6 years and older Published 08 April 2019 1 Product update SMC2139 mepolizumab 100mg powder for solution for injection (Nucala®) GlaxoSmithKline UK Limited 8 March 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice (...) is summarised as follows: ADVICE: following an abbreviated submission mepolizumab (Nucala®) is accepted for restricted use within NHSScotland. Indication under review: as an add-on treatment for severe refractory eosinophilic asthma in adolescents and children aged 6 years and older. SMC restriction: patients who have eosinophils of at least 150 cells per microlitre (0.15 x 10 9 /L) at initiation of treatment and have had at least four asthma exacerbations in the preceding year or are receiving maintenance

2019 Scottish Medicines Consortium

110. Benralizumab (asthma) - Addendum to Commission A18-11

Benralizumab (asthma) - Addendum to Commission A18-11 1 Translation of addendum A18-42 Benralizumab (Asthma) – Addendum zum Auftrag A18-11 (Version 1.0; Status: 13 July 2018). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Addendum 13 July 2018 1.0 Commission: A18-42 Version: Status: IQWiG Reports – Commission No. A18-42 Benralizumab (asthma) – Addendum (...) to Commission A18-11 1 Addendum A18-42 Version 1.0 Benralizumab – Addendum to Commission A18-11 13 July 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Benralizumab (asthma) – Addendum to Commission A18-11 Commissioning agency: Federal Joint Committee Commission awarded on: 26 June 2018 Internal Commission No.: A18-42 Address of publisher: Institut für Qualität und Wirtschaftlichkeit im

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

111. Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma Full Text available with Trip Pro

Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma Sublingual allergen immunotherapy (SLIT) has been demonstrated to be both clinically efficacious and safe. However, in line with the current regulatory guidance from the European Medicines Agency, allergen immunotherapy (AIT) products must demonstrate their efficacy and safety in pivotal phase III trials for registration.We sought to investigate (...) the efficacy and safety of sublingual high-dose liquid birch pollen extract (40,000 allergy units native [AUN]/mL) in adults with birch pollen allergy.A randomized, double-blind, placebo-controlled, parallel-group multicenter trial was conducted in 406 adult patients with moderate-to-severe birch pollen-induced allergic rhinoconjunctivitis with or without mild-to-moderate controlled asthma. Treatment was started 3 to 6 months before the birch pollen season and continued during the season in 40 clinical

2019 EvidenceUpdates

112. High-Dose Vitamin D Supplementation During Pregnancy and Asthma in Offspring at the Age of 6 Years. Full Text available with Trip Pro

High-Dose Vitamin D Supplementation During Pregnancy and Asthma in Offspring at the Age of 6 Years. 30860552 2019 03 25 2019 09 12 1538-3598 321 10 2019 03 12 JAMA JAMA High-Dose Vitamin D Supplementation During Pregnancy and Asthma in Offspring at the Age of 6 Years. 1003-1005 10.1001/jama.2019.0052 Brustad Nicklas N Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte University Hospital, Copenhagen, Denmark. Eliasen Anders U AU Copenhagen Prospective Studies on Asthma (...) in Childhood, Herlev and Gentofte University Hospital, Copenhagen, Denmark. Stokholm Jakob J Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte University Hospital, Copenhagen, Denmark. Bønnelykke Klaus K Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte University Hospital, Copenhagen, Denmark. Bisgaard Hans H Copenhagen Prospective Studies on Asthma in Childhood, Herlev and Gentofte University Hospital, Copenhagen, Denmark. Chawes Bo L BL Copenhagen

2019 JAMA Controlled trial quality: uncertain

113. Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma Full Text available with Trip Pro

Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma Long-term oral corticosteroid (OCS) use in patients with severe asthma is associated with significant adverse effects.This 40-week, randomised, double-blind trial evaluated the OCS-sparing potential of tralokinumab in patients with severe, uncontrolled asthma requiring maintenance OCS treatment plus inhaled corticosteroids/long-acting β2-agonists. Overall, 140 patients were randomised to tralokinumab 300 mg (...) or placebo (n=70 in each group) administered subcutaneously every 2 weeks. The primary end-point was percentage change from baseline in average OCS dose at week 40, while maintaining asthma control. Secondary end-points included proportion of patients with a prescribed maintenance OCS dose of ≤5 mg, those with a ≥50% reduction in prescribed maintenance OCS dose and asthma exacerbation rate. Safety was also assessed.At week 40, the percentage reduction from baseline in the final daily average OCS dose

2019 EvidenceUpdates

114. Less puffing, more breathing? Intermittent inhaled steroids for asthma

with intermittent treatment. 1,2 • Previous systematic review 3 (6 RCTs; 1211 children and adults) of intermittent versus daily ICS (excluded ICS/LABA combination trials) found: o No difference in risk of exacerbation. o Fewer asthma-controlled days with intermittent versus daily ICS. o For children: daily ICS resulted in ~0.5cm less growth (height) at ~1 year. 3 Context: • Up to 75% of asthmatics have mild asthma. 4 • Guidelines recommend daily ICS for mild persistent asthma, 5 but only ~50% adhere. 6 (...) Less puffing, more breathing? Intermittent inhaled steroids for asthma March 4, 2019 (en français) Less puffing, more breathing? Intermittent inhaled steroids for asthma Clinical Question: In patients with mild persistent asthma, is intermittent use of inhaled corticosteroids (ICS) as effective as daily use? Bottom Line: In patients with mild persistent asthma, intermittent use of ICS or ICS/LABA is similar to daily ICS in preventing exacerbations but is associated with ~5 fewer weeks per year

2019 Tools for Practice

115. Benralizumab for treating severe eosinophilic asthma

Benralizumab for treating severe eosinophilic asthma Benr Benralizumab for treating se alizumab for treating sev vere ere eosinophilic asthma eosinophilic asthma T echnology appraisal guidance Published: 6 March 2019 www.nice.org.uk/guidance/ta565 © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights). Last updated September 2019Y Y our responsibility our responsibility The recommendations in this guidance represent (...) inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Benralizumab for treating severe eosinophilic asthma (TA565) © NICE 2019. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Last updated September 2019 Page 2 of 23Contents Contents 1 Recommendations 4 2

2019 National Institute for Health and Clinical Excellence - Technology Appraisals

116. Acceptance and Commitment Therapy for Parental Management of Childhood Asthma: An RCT Full Text available with Trip Pro

Acceptance and Commitment Therapy for Parental Management of Childhood Asthma: An RCT Few trials have been conducted to address the psychological difficulties of parents in managing their child's asthma. Fostering parental psychological flexibility through Acceptance and Commitment Therapy (ACT) may help parents to accept these psychological difficulties and improve their management of childhood asthma.In this randomized controlled trial, a 4-session, group-based ACT plus asthma education (ACT (...) group) was compared with an asthma education talk plus 3 telephone follow-ups (control group) to train parents of children diagnosed with asthma. The use of health care services due to asthma exacerbations in children and the psychological well-being of their parents were assessed before, immediately after, and at 6 months after the intervention.A total of 168 parents and their children aged 3 to 12 years with asthma were consecutively recruited in a public hospital in Hong Kong. When compared

2019 EvidenceUpdates

117. Serious asthma events with mometasone furoate plus formoterol compared with mometasone furoate Full Text available with Trip Pro

Serious asthma events with mometasone furoate plus formoterol compared with mometasone furoate The safety of long-acting β-agonists added to inhaled corticosteroids for the treatment of persistent asthma has been controversial.We sought to determine whether administering formoterol in combination with mometasone furoate increases the risk of serious asthma outcomes (SAOs) compared with mometasone furoate alone. This clinical trial is registered as NCT01471340.We conducted a 26-week, randomized (...) , double-blind trial in adolescent and adult patients (≥12 years) with persistent asthma in 35 countries with the primary objective of evaluating whether mometasone furoate-formoterol increases the risk of SAOs (adjudicated hospitalization, intubation, or death) compared with mometasone furoate alone. The key efficacy end point was asthma exacerbation (composite of hospitalization of ≥24 hours, emergency department visits of <24 hours requiring systemic corticosteroids, or use of systemic

2019 EvidenceUpdates

118. Mepolizumab (asthma) - Benefit assessment according to §35a Social Code Book V

Mepolizumab (asthma) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of the executive summary of the dossier assessment Mepolizumab (Asthma bei Jugendlichen und Kindern ab 6 Jahren) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 20 December 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English- language readers. However, solely the German original text is absolutely authoritative (...) and legally binding. IQWiG Reports – Commission No. A18-58 Mepolizumab (asthma in adolescents and children aged 6 years and older) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A18-58 Version 1.0 Mepolizumab (asthma in adolescents and children aged 6 years and older) 20 December 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Mepolizumab (asthma

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

119. Dupilumab (asthma) - Benefit assessment according to §35a Social Code Book V

Dupilumab (asthma) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Dupilumab (Asthma) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 28 November 2019). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. 19-74 Dupilumab (asthma) – Benefit (...) assessment according to §35a Social Code Book V 1 Extract of dossier assessment A19-74 Version 1.0 Dupilumab (asthma) 28 November 2019 Institute for Quality and Efficiency in Health Care (IQWiG) - 1 - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Dupilumab (asthma) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission awarded on: 29 August 2019 Internal Commission No.: A19-74 Address of publisher

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

120. The long-term effect of an exercise and diet intervention in asthma patients: a 1-year follow-up on a randomised controlled trial. Full Text available with Trip Pro

The long-term effect of an exercise and diet intervention in asthma patients: a 1-year follow-up on a randomised controlled trial. In the EFFORT (Effects of Exercise and Diet in Nonobese Asthma Patients - A Randomized Controlled Trial) study, maximum exercise capacity (V'O2max) increased significantly within a 2-month high-intensity spinning period. Furthermore, the study concluded that only the combined exercise and diet intervention improved asthma control, significantly. This study examined (...) whether original improvements in V'O2max and asthma control were present 1 year after intervention completion.In the original trial, 149 patients were randomised into four study groups. Participants were assessed with an incremental cycle ergometer test and the Asthma Control Questionnaire (ACQ). Of the 149 patients, 66 accepted the follow-up invitation. Participants were distributed in their original groups: exercise group (n=18), diet group (n=117), combined diet and exercise group (n=115

2019 ERJ open research Controlled trial quality: uncertain